<DOC>
	<DOCNO>NCT00403637</DOCNO>
	<brief_summary>The study design obtain safety efficacy data three dose level indacaterol deliver via SDDPI patient persistent asthma . All patient receive 1 day treatment follow : indacaterol 150 µg , indacaterol 300 µg , indacaterol 600 µg , placebo , formoterol . Each treatment day follow washout-period 1 week</brief_summary>
	<brief_title>Efficacy Safety Single Doses Indacaterol Delivered Via Single Dose Dry Powder Inhaler ( SDDPI ) Compared Placebo Patients With Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Males females 12 75 year age diagnosis persistent asthma Daily treatment bronchodilator daily dose least 100 µg beclomethasone dipropionate equivalent FEV1 Visit 1 least 50 % predict normal value FEV1 reversibility least 15 % Use tobacco product within 6 month prior Visit 1 smoke history 10 pack year Chronic Obstructive Pulmonary Disease ( COPD ) Seasonal allergy asthma likely deteriorate period study Emergency room treatment acute asthma attack within previous 6 week hospitalize within previous 6 month A respiratory tract infection within previous 6 week Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Asthma , indacaterol , long act β2-agonist</keyword>
</DOC>